The FDA peptides vote is days away. This insider expects approval

Jul 15, 2026 · 1:01:14

Listen to Episode

✨ AI Summary

Dr. Jesse Morse discusses the FDA's upcoming peptide review and market impact.
He highlights how 2023 restrictions pushed demand into unregulated markets.
Morse breaks down the 7 peptides under review and their potential.

Guests on This Episode

JM

Jesse Morse

1 podcast appearance

More from Hims House

Enhanced Group CEO: Hot peptide summer is coming — but likely not till 2027

Aug 7, 2026 · 0:54:27

🚨 FDA committee votes "YES" on 6 of 7 peptides — here's what happens next, with Dr. Alex Tatem

Jul 27, 2026 · 0:59:34

Ryan MacDonald: Peptides could be a $30B+ market, and Hims is positioned to win meaningful share

Jul 7, 2026 · 1:00:30

🚨 EXCLUSIVE: Hims board member David Wells on why he bought $1.2M of Hims

Jul 1, 2026 · 0:51:24

View all episodes →